{"id":"W4410805300","doi":"10.1200/jco.2025.43.16_suppl.tps9600","title":"A phase 1, open-label, dose expansion cohort of the tolerability of tolododekin alfa (ANK-101) in combination with cemiplimab in cutaneous squamous cell carcinoma.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nonmelanoma Skin Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Tolerability; Open label; Cohort; Oncology; Internal medicine; Adverse effect","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003091631,0.0001603103,0.002127691,0.0001983931,0.00002907633,0.000004313025,0.0004134798,0.0002914044,0.00003042193],"category_scores_gemma":[0.002762736,0.0001002079,0.0001482752,0.0005136656,0.0004576409,0.0000874689,0.0002612707,0.0009888519,5.582248e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004642823,"about_ca_system_score_gemma":0.002430005,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000370468,"about_ca_topic_score_gemma":0.001039714,"domain_scores_codex":[0.9953464,0.0007612295,0.003015292,0.0002680341,0.0003954305,0.0002135894],"domain_scores_gemma":[0.9936301,0.003024183,0.002345931,0.0004026401,0.0005088535,0.00008832416],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02075345,0.02012441,0.9357476,0.000190975,0.0000763275,0.0004877945,0.0003447805,0.00006692258,0.000740232,0.00006559704,0.0004663582,0.02093561],"study_design_scores_gemma":[0.06535105,0.02418136,0.9057468,0.0003626898,0.0002916407,0.0001807443,0.0003112862,0.0002804002,0.00222383,0.0004672194,0.0005141632,0.00008884123],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9889359,0.0005893831,0.00004201326,0.004138218,0.000539242,0.0009059794,0.000005565002,0.000002077314,0.004841547],"genre_scores_gemma":[0.9979919,0.0001411785,0.001152746,0.0005198954,0.00004974911,0.00001509371,0.000001308395,0.00001064785,0.0001175191],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04459761,"threshold_uncertainty_score":0.4310725,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07668714375346083,"score_gpt":0.4439034854278719,"score_spread":0.3672163416744111,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}